Ozempic causes gastrointestinal side effects in a large percentage of users, with nausea being the most common, affecting roughly 44% of people in clinical trials. Most of these effects are mild to moderate and fade within the first few weeks, but some side effects are more serious and worth understanding before you start treatment.
Digestive Side Effects Are the Most Common
The stomach and intestinal issues are hard to ignore. In clinical trials of semaglutide (Ozempic’s active ingredient) at the 2.4 mg weight loss dose, 44% of participants experienced nausea, compared to 16% on placebo. Diarrhea hit about 30%, vomiting affected 25%, and constipation showed up in 24%. These numbers are significantly higher than what people on a placebo reported, so they reflect genuine drug effects rather than the experience of dieting alone.
The reason these symptoms are so prevalent comes down to how the drug works. Semaglutide mimics a gut hormone called GLP-1, which activates receptors in a part of the brainstem that sits outside the brain’s normal protective barrier. This region is closely tied to nausea signaling. At the same time, the drug slows the physical contractions of your stomach after meals and increases pressure at the stomach’s exit valve, which means food sits in your stomach longer than usual. That combination of brain-level nausea signaling and slower digestion accounts for most of the discomfort.
When Side Effects Peak and Fade
GI side effects are most intense during the first four weeks of treatment and during each dose increase. Ozempic is prescribed on a gradual schedule: you start at 0.25 mg weekly for four weeks, then move to 0.5 mg, with possible increases up to a maximum of 2 mg. Each step up can temporarily reignite nausea or other stomach symptoms as your body adjusts.
For most people, nausea is mild to moderate and fades after the dose escalation phase. In the STEP 3 clinical trial, only about 6% of participants on semaglutide discontinued treatment because of adverse events, mostly gastrointestinal ones. That means the vast majority of people who experience stomach issues find them manageable enough to continue. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help during those early adjustment weeks.
Delayed Stomach Emptying and Gastroparesis
Beyond ordinary nausea, some people develop a more persistent problem: significantly delayed gastric emptying, sometimes called gastroparesis. About 19% of patients on GLP-1 drugs develop measurably delayed stomach emptying, and semaglutide carries a 3.3 times higher gastroparesis risk compared to another weight loss medication (bupropion-naltrexone) and a 6.1 times higher risk compared to sleeve gastrectomy surgery.
Gastroparesis feels like prolonged fullness, bloating, and nausea that doesn’t resolve in the expected timeline. It can become more pronounced with rapid dose increases. If you’re experiencing persistent nausea that doesn’t improve after several weeks at a stable dose, that’s worth bringing up with your prescriber, as it may signal more than typical adjustment symptoms.
Muscle Loss Alongside Fat Loss
Weight loss from semaglutide comes primarily from fat, but not exclusively. A systematic review of six clinical trials covering over 1,500 adults found that lean mass (mostly muscle) accounted for anywhere from nearly 0% to 40% of total weight lost, depending on the study. That’s a wide range, and the trials with larger patient groups tended to show more concerning levels of muscle loss.
This matters because losing muscle can lower your metabolic rate, reduce physical strength, and increase injury risk, particularly for older adults. Resistance training and adequate protein intake during treatment can help preserve muscle, though the drug itself doesn’t selectively protect lean tissue.
Facial Volume Loss
The cosmetic phenomenon sometimes called “Ozempic face” refers to noticeable facial aging that can accompany rapid weight loss on the drug. Fat loss in the temples, cheeks, jawline, and around the nasolabial folds can make a person look gaunt or older than they did before treatment. The underlying cause is straightforward: when fat beneath facial skin shrinks quickly, the skin doesn’t have time to remodel its collagen and tighten to match. The result is sagging and hollowing in areas where subcutaneous fat once provided volume.
Levels of collagen and elastin in the skin also appear to decrease. Some researchers believe the drug simply accelerates the visible effects of normal age-related elastin decline by removing the fat layer that was masking it. This effect is more pronounced with larger or faster amounts of weight loss and tends to be more noticeable in people over 40.
Pancreatitis and Gallbladder Problems
Pancreatitis, an inflammation of the pancreas that causes severe abdominal pain, has been reported with GLP-1 drugs including semaglutide. The exact risk level remains debated, but cases are documented across this drug class. Symptoms to be aware of include sudden, severe pain in the upper abdomen that may radiate to the back, often accompanied by nausea and vomiting that feels different from the drug’s usual GI effects.
Gallbladder disease, particularly gallstones and bile duct stones, has also been linked to GLP-1 drugs. The connection may involve the drug’s effects on upper GI motility. Rapid weight loss from any cause increases gallstone risk, so it can be difficult to separate the drug’s direct effect from the weight loss itself. Pain in the upper right abdomen, especially after eating fatty foods, is the hallmark symptom.
Thyroid Cancer Risk
Ozempic carries a boxed warning, the FDA’s most serious label, regarding thyroid tumors. In rodent studies, stimulating the GLP-1 receptor caused proliferation of thyroid C cells and eventually led to medullary thyroid carcinoma. Whether this translates to humans remains uncertain, but the concern was significant enough for regulators to act on it.
Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you have either of these in your medical history, this drug is not an option. For everyone else, the practical takeaway is to be aware of symptoms like a lump or swelling in the neck, difficulty swallowing, hoarseness, or shortness of breath.
How the Dosing Schedule Reduces Side Effects
The graduated dosing schedule exists specifically to minimize side effects. Starting at 0.25 mg for four weeks gives your body time to adapt before the dose increases to 0.5 mg. From there, your prescriber may increase to 1 mg or eventually 2 mg, with at least four weeks between each step. Skipping steps or escalating too quickly has been linked to more severe gastroparesis and worse GI symptoms overall.
If side effects are persistent at a given dose, staying at that level for longer than the minimum four weeks before increasing is a common strategy. Some people find that their optimal dose for tolerability is lower than the maximum, and the weight loss benefits may still be meaningful at 0.5 mg or 1 mg without the intensity of side effects seen at higher doses.